Glycitop 60mg Tablet MR contains Gliclazide, a sulfonylurea class antidiabetic agent, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. The modified-release (MR) formulation ensures a sustained release of the active ingredient, providing a prolonged hypoglycemic effect and enhancing patient compliance through once-daily dosing. Glycitop 60mg is typically prescribed as part of a comprehensive diabetes management plan, including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to sulfonylureas. Caution is advised in patients with a history of cardiovascular disease or those prone to hypoglycemia. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Dose adjustments may be necessary based on glycemic response and patient tolerance. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Glycitop 60mg Tablet MR should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.